Viatris (WBO:MYL) Beta: 0.5257 (As of Jun. 26, 2026)


WBO:MYL Viatris Inc WBO:MYL
47 GF Score
Price €14.28
GF Value €9.78
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Viatris Beta?

Viatris WBO:MYL +1.52% 47 Beta is 0.5257 as of Jun. 26, 2026. GuruFocus rates WBO:MYL with a GF Score™ of 47/100 and a GF Value™ of €9.78 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Viatris's Beta is 0.5257.


Viatris  (WBO:MYL) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Viatris Beta Related Terms


Viatris Beta Historical Data

* Premium members only.

The historical data trend for Viatris's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Beta Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.55 0.83 -0.13 0.01

Viatris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.41 0.47 0.01 0.27

WBO:MYL vs NBIX, UTHR, ELAN: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viatris Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Beta distribution charts can be found below:

* The bar in red indicates where Viatris's Beta falls into.


WBO:MYL
47GF Score
Viatris Inc WBO:MYL
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viatris Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.5257 mean?
Viatris (WBO:MYL) has a Beta of 0.5257 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Viatris and its competitors.
Is Viatris' Beta too high?
Viatris' current Beta is 0.5257. Overall, Viatris has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Beta compare to NBIX and UTHR?
Viatris' Beta of 0.5257 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Viatris and its competitors. Viatris's current Beta is 0.5257. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (WBO:MYL) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.78, compared to a current price of €14.28 — trading 46% above its estimated fair value. The current Beta is 0.5257. Viatris' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Viatris (WBO:MYL), the current Beta is 0.5257 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (WBO:MYL) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of €14.28 is trading 46% above its estimated GF Value™ of €9.78. GuruFocus considers Viatris to be Significantly Overvalued.

Key valuation signals for WBO:MYL:

  • Beta: 0.5257
  • GF Value™: €9.78 vs. price of €14.28 (46% above fair value)
  • GF Score™: 47/100 with 7 warning signs

No single metric tells the full story. See the WBO:MYL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
47GF Score

Get the complete analysis for WBO:MYL

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.28
Price
€9.78
GF Value